Topics

Gene Therapy Developer Passage Bio Files for $125M IPO

15:40 EST 3 Feb 2020 | Genetic Engineering News

Passage Bio, a developer of gene therapies for rare monogenic CNS diseases whose co-founders include pioneer researcher James M. Wilson, MD, PhD, has disclosed plans to raise $125 million through an initial public offering, according to a registration statement filed with the U.S. Securities and Exchange Commission.

The post Gene Therapy Developer Passage Bio Files for $125M IPO appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: Gene Therapy Developer Passage Bio Files for $125M IPO

NEXT ARTICLE

More From BioPortfolio on "Gene Therapy Developer Passage Bio Files for $125M IPO"

Quick Search

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...